X0306 4 2014-06-06 0 0001428522 Radius Health, Inc. RDUS 0001358312 MPM BioVentures IV LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON MA 02116 0 0 1 0 0001356950 Scopa James Paul C/O MPM ASSET MANAGEMENT 601 GATEWAY BLVD., SUITE 350 SOUTH SAN FRANCISCO CA 94080 0 0 1 0 0001358311 MPM BioVentures IV GP LLC C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON MA 02116 0 0 1 0 0001423213 MPM Bio IV NVS Strategic Fund LP C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON MA 02116 0 0 1 0 0001473930 Foley Todd C/O MPM ASSET MANAGEMENT 200 CLAREDON STREET, 54TH FLOOR BOSTON MA 02116 0 0 1 0 0001180429 KAILIAN VAUGHN M C/O MPM ASSET MANAGEMENT 200 CLARENDON STREET, 54TH FLOOR BOSTON MA 02116 0 0 1 0 Common Stock 2014-06-06 4 C 0 549548 A 549548 I See footnote Common Stock 2014-06-06 4 C 0 883993 A 1433541 I See footnote Common Stock 2014-06-06 4 C 0 314204 A 1747745 I See footnote Common Stock 2014-06-06 4 J 0 393802 A 2141547 I See footnote Series A-1 Convertible Preferred Stock 2014-06-06 4 C 0 114537 0.00 D Common Stock 549548 0 I See footnote Series A-2 Convertible Preferred Stock 2014-06-06 4 C 0 184242 0.00 D Common Stock 883993 0 I See footnote Series B Convertible Preferred Stock 2014-06-06 4 C 0 71638 0.00 D Common Stock 314204 0 I See footnote The shares were converted into Common Stock by MPM Bio IV NVS Strategic Fund, L.P. ("MPM NVS"). MPM BioVentures IV GP LLC ("BV IV GP LLC") and MPM BioVentures IV LLC ("BV IV LLC") are the direct and indirect general partners of MPM NVS. Luke Evnin, Ansbert Gadicke, Todd Foley, Vaughn M. Kailian and James Paul Scopa are the members of BV IV LLC. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein. The Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series A-3 Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.798-for-1 basis upon the listing of the Issuer's Common Stock on a national securities exchange and had no expiration date. The shares are held by MPM NVS. Each reporting person disclaims beneficial ownership of the securities reported herein except to the extent of his or its respective pecuniary interest therein. The Series B Convertible Preferred Stock automatically converted into the Issuer's Common Stock on a 4.386-for-1 basis upon the listing of the Issuer's Common Stock on a national securities exchange and had no expiration date. In connection with the listing of the Issuer's Common Stock on a national securities exchange, the Issuer issued shares of its Common Stock to its Series A-1, Series A-2, Series A-3 and Series B convertible preferred stock in satisfaction of accumulated and unpaid dividends. /s/ Luke Evnin, Member of MPM BioVentures IV LLC 2014-06-10 /s/ James Paul Scopa 2014-06-10 /s/ Luke Evnin, Member of MPM BioVentures IV LLC, the Managing Member of MPM BioVentures IV GP LLC 2014-06-10 /s/ Luke Evnin, Member of MPM BioVentures IV LLC, the Managing Member of MPM BioVentures IV GP LLC, the general partner of MPM Bio IV NVS Strategic Fund. L.P. 2014-06-10 /s/ Todd Foley 2014-06-10 Vaughn M. Kailian 2014-06-10